Identification of Amino Acid Residues Important for Ligand Binding to Fas
暂无分享,去创建一个
Jürgen Bajorath | Jeffrey A. Ledbetter | Alejandro Aruffo | J. Bajorath | P. Kiener | A. Aruffo | J. Ledbetter | G. Starling | J. Emswiler | Peter A. Kiener | Gary C. Starling | John Emswiler
[1] C. Smith,et al. Identification of a source of biologically active CD40 ligand , 1992, European journal of immunology.
[2] N. Jenkins,et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand , 1994, Cell.
[3] S. Nagata,et al. Lethal effect of the anti-Fas antibody in mice , 1993, Nature.
[4] S. Nagata,et al. The Fas death factor , 1995, Science.
[5] J Bajorath,et al. Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis. , 1995, Biochemistry.
[6] D. Banner,et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation , 1993, Cell.
[7] J Bajorath,et al. Identification of residues on CD40 and its ligand which are critical for the receptor-ligand interaction. , 1995, Biochemistry.
[8] J. Tschopp,et al. Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.
[9] S. Marsters,et al. Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding. , 1992, The Journal of biological chemistry.
[10] G. Sutherland,et al. Moslecular and biological characterization of human 4‐1BB and its ligands , 1994, European journal of immunology.
[11] P. Kiener,et al. Activation of human monocytes through CD40 induces matrix metalloproteinases. , 1996, Journal of immunology.
[12] Jürgen Bajorath,et al. Prediction of the three-dimensional structure of the human Fas receptor by comparative molecular modeling , 1997, J. Comput. Aided Mol. Des..
[13] S. Nagata,et al. Apoptosis: Telling cells their time is up , 1996, Current Biology.
[14] J. Menonna,et al. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain , 1996, The Journal of experimental medicine.
[15] N. Copeland,et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.
[16] P. Kiener,et al. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils , 1996, The Journal of experimental medicine.
[17] A. Aruffo,et al. Cleavable CD40Ig fusion proteins and the binding to sgp39. , 1995, Journal of immunological methods.
[18] Stephen W. Fesik,et al. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain , 1996, Nature.
[19] F. Shanahan,et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.
[20] P. Galle,et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage , 1995, The Journal of experimental medicine.
[21] K. Sullivan,et al. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. , 1996, The New England journal of medicine.
[22] B. Modrell,et al. The Membrane-proximal Scavenger Receptor Cysteine-rich Domain of CD6 Contains the Activated Leukocyte Cell Adhesion Molecule Binding Site (*) , 1995, The Journal of Biological Chemistry.
[23] K. Yoshino,et al. Metalloproteinase-mediated Release of Human Fas Ligand , 1995 .
[24] I. Stamenkovic,et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co‐stimulatory activity. , 1992, The EMBO journal.